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1  | INTRODUC TION
Pattern recognition receptors (PRRs) have a central role in regulat-
ing immune and inflammatory responses, and the magnitude of their 
responses can affect the outcome of infections, autoimmune and 
inflammatory diseases, and cancer risk. Among the most well-char-
acterized PRRs are the nucleotide-binding oligomerization domain 
(NOD)-like receptors (NLRs). The NLRs are cytosolic receptors which 
sense microbial motifs, endogenous byproducts of tissue injury, and 
environmental signals; however, mechanisms by which each NLR 
member recognizes different signals are still not well-understood. 
Once activated, they mediate various effector functions via sig-
nal transduction pathways that regulate processes such as cellular 
death and proliferation, autophagy, tissue repair, and inflammation. 
Consequently, NLRs are important in maintaining tissue and im-
mune homeostasis that when dysregulated can lead to inflammatory 
diseases. NOD1 and NOD2 are two seminal NLRs that have been 
shown to sense specific bacterial ligands and have diverse immu-
nomodulatory effects that are important for both host defense and 
tissue homeostasis. In this review, we will describe host responses 
regulated by NOD1 and NOD2 and their impact on host-microbial 
interactions and inflammatory disease pathogenesis.
2  | STRUC TURE OF NOD1 AND NOD2 
RECEPTORS
NLRs are characterized by a tripartite domain structure consisting 
of a C-terminal leucine-rich repeat (LRR) domain required for ligand 
sensing, a central long nucleotide-binding NACHT domain (NBD do-
main) that mediates oligomerization, and a variable N-terminal ef-
fector domain important for interactions with downstream effector 
proteins. NLRs are further divided into four subfamilies based on the 
nature of their N-terminal domain: (i) NLRP contain a pyrin domain 
(PYD), (ii) NLRA contain an acidic transcriptional activation (TA) do-
main, (iii) NLRB have a baculovirus IAP repeat (BIR) domain, and (iv) 
NLRC have a caspase activation and recruitment domain (CARD), 
respectively. As founding members of the NLRs, NOD1 and NOD2 
have often retained their original nomenclature; however, since they 
contain an N-terminal CARD domain, they belong to the NLRC sub-
family of NLRs and are technically designated as NLRC1 and NLRC2, 
respectively.1 NOD1 and NOD2 have similar domain architectures, 
but differ in the number of CARD domains: NOD1 contains one, 
whereas two tandem CARD domains are found in NOD2 (Figure 1). 
Systematic mutagenesis experiments have been informative in 
delineating the functions of the various domains in the activity of 
NOD1 and NOD2. The CARD domain is critical for interaction with 
the downstream adapter protein RIP2 with crucial residues in both 
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Abstract
It has been long recognized that NOD1 and NOD2 are critical players in the host im-
mune response, primarily by their sensing bacterial peptidoglycan-conserved motifs. 
Significant advances have been made from efforts that characterize their upstream 
activators, assembly of signaling complexes, and activation of downstream signaling 
pathways. Disruption in NOD1 and NOD2 signaling has also been associated with 
impaired host defense and resistance to the development of inflammatory diseases. 
In this review, we will describe how NOD1 and NOD2 sense microbes and cellular 
stress to regulate host responses that can affect disease pathogenesis and outcomes.
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CARD domains of Nod2 important for this activity.2-5 Within the 
centrally located NBD are Walker A- and B box motifs that contain 
residues important for ATP binding and hydrolysis as well as ligand-
dependent activation of downstream signaling pathways, notably 
NF-κB.5,6 ATP binding by NOD2 enhances both ligand binding and 
oligomerization, and mutations in this region that disrupt this can ab-
rogate downstream signaling.6,7 On the other hand, inhibition of ATP 
hydrolysis and stabilization of binding results in increased activity. 
Interestingly, mutations in a highly conserved patch of acidic residues 
(extended Walker B box) in NOD2 that have been associated with 
autoinflammatory diseases, such as early-onset sarcoidosis and Blau 
syndrome, result in constitutive activation of NOD2, but inactivation 
of NOD1, suggesting that despite strong similarities in domain struc-
ture, different mechanisms are involved in their activation.6
The C-terminal LRR domain differs in size between NOD1 and 
NOD2 and is crucial for ligand recognition and binding.8,9 Comparative 
genomic studies show high conservation particularly within the LRR 
among different species in residues especially along a predicted con-
cave surface of the LRRs to form a ligand binding site,10 which is also 
consistent with the crystal structure of NOD2.11 Furthermore, the LRR 
is solely responsible for dictating ligand specificity.5,8
3  | AC TIVATORS OF NOD1 AND NOD2
NOD1 and NOD2 recognize distinct fragments of peptidogly-
can (PGN) that is a major component of the bacterial cell wall of 
Gram-positive bacteria, outside the cytoplasmic membrane, pro-
viding them structure, rigidity, and protection.12,13 A thin layer of 
PGN is also found in Gram-negative bacteria within the periplas-
mic space. PGN consists of a polymeric chain of alternating sugar 
residues of N-acetylglucosamine (GlcNAc) and N-acetylmuramic 
acid (MurNAc) that form the backbone with short peptides cova-
lently bound to MurNAc to create a muramyl peptide, which can 
be cross-linked to form the lattice structure of peptidoglycan 14 
(Figure 2). The short peptide chains in the PGN contain 3-5 amino 
acids that are differentially found in Gram-negative and Gram-
positive bacteria and are also differentially recognized by NOD1 
and NOD2.14 Muropeptides are peptidoglycan fragments that can 
be generated by degradation of PGN either by host or by bacte-
rial enzymes. NOD1 senses muropeptides containing the mini-
mal γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) dipeptide 
core, which is predominantly found in Gram-negative, but also 
in a few Gram-positive bacteria such as Listeria monocytogenes 
and Bacillus spp.15,16 Interestingly, screening of bacteria derived 
from soil revealed that the genus Bacillus bacteria has the strong-
est NOD1-stimulatory effect associated with culture supernatants 
rather than bacterial cell extracts and is also highly stable, more so 
than Toll-like receptor 4 (TLR4) or NOD2 ligands, suggesting the 
potential for environmental stimuli to contribute to homeostatic 
regulation of the immune system and that NOD1 agonists can be 
produced and released by bacteria to activate NOD1.17 Indeed, 
muramyl peptides spontaneously shed by the Shigella are able to 
trigger a NOD1-mediated response, and Listeria lacking streptoly-
sin O, which is required to escape from the phagosome into the cy-
tosol, is still able to activate NOD1.17,18 Furthermore, the synthetic 
addition of lipophilic acyl residues greatly enhanced Nod1 activa-
tion and may be related to interaction with the cell membrane to 
F I G U R E  1   Schematic representation of NOD-like receptors 1 and 2. NOD1 consists of one N-terminal caspase activation and 
recruitment domain (CARD), and NOD2 has two in tandem. In both receptors, the domain CARD is followed by a core nucleotide-binding 
domain (NBD) and a C-terminal leucine-rich repeat domain (LRR). In the absence of ligand, NOD1 and NOD2 are in an inactive monomeric 
form, maintained by the binding of LRR domain into NBD and stabilized by chaperone proteins, such as HSP70 or HSP90. Upon recognition 
of PGN (peptidoglycan) ligands, a conformational change occurs, resulting in homo-oligomerization of two NOD molecules that once 
activated trigger inflammatory signaling pathways
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facilitate translocation into the intracellular compartment of the 
host cell for recognition by NOD1.19 Although a direct interaction 
between NOD1 and the ligand l-Ala-γ-D-Glu-meso-diaminopimelic 
acid (TriDAP) that is LRR-dependent has been demonstrated by 
surface plasmon resonance and atomic microscopy,20 it remains 
unclear whether this is true for all ligands and whether other co-
factors are involved in ligand binding.
In contrast to NOD1, NOD2 requires PGN fragments contain-
ing an intact MurNac ring structure and an attached sugar to the 
dipeptide moiety and has been shown to directly bind muramyl 
dipeptide (MDP) that is broadly expressed in both Gram-positive 
and Gram-negative bacteria.21-23 To activate NOD2, MDP may 
have an intact MurNAc ring structure, and the sugar must be 
attached to the peptide moiety.23 Unlike NOD1, the length of 
the peptide moiety is not critical for recognition, and therefore, 
meso-DAP-muropeptides can be recognized by both NOD1 
and NOD2, allowing NOD2 to be activated by a broader range 
of muropeptides from both Gram-negative and Gram-positive 
bacteria.14 Although several studies have demonstrated a direct 
interaction between NOD2 and MDP,7,22,24 it remains to be deter-
mined whether direct binding occurs with larger MDP-containing 
PGN fragments and whether additional accessory proteins are 
involved. For example, it has been shown that glucosaminyl-MDP 
is capable of binding to YB1, which can form a complex with 
NOD2 leading to cooperative activation of downstream signaling 
pathways.25
There is some evidence to suggest that in addition to bacterial 
peptidoglycan fragments, NOD1 and NOD2 can recognize other 
types of ligands such as viral RNA. Both in vitro experiments with 
overexpressed proteins and in vivo studies using Nod2-deficient mice 
demonstrated the ability of viral single-stranded RNA (ssRNA) to ac-
tivate NOD2 that is dependent on the presence of both the NBD and 
LRR domains. However, ssRNA is unable to activate NOD1.26 Rather, 
at least in vitro in a hepatocyte cell line, synthetic dsRNA (polyI:C) or 
dsRNA generated by the RNA polymerase of hepatitis C virus induces 
NOD1 expression and interacts with NOD1, resulting in activation 
of downstream signaling pathways.27 Interestingly, this interaction 
occurred independently of the LRR, but requires an intact NBD for 
full activity.27 Similarly, zebrafish NOD1 overexpressed in the carp 
fish cell line epithelioma papulosum cyprinid (EPC) was capable of 
binding to the dsRNA virus, spring viremia of carp virus (SVCV), as 
well as polyI:C that was CARD-dependent, suggesting perhaps the 
involvement of an intermediary protein for this interaction.28
Besides pathogen-associated molecular patterns (PAMPs), 
there is increasing evidence that NOD1 and NOD2, like other 
NLRs, can also respond to danger signals or damage-associ-
ated molecular patterns (DAMPs). Notably, disturbances in en-
doplasmic reticulum (ER) function can lead to ER stress with 
F I G U R E  2   Basic structure of peptidoglycan (PGN) motifs recognized by NOD1 and NOD2. Lys-PGN is present in Gram-positive bacteria, 
whereas DAP-PGN constitutes the cell wall of Gram-negative bacteria. Abbreviations: D-Ala: D-alanine; D-Glu: D-glutamic acid; GlcNAc: 
N-acetylglucosamine; L-Ala: L-alanine; L-Lys: L-lysine; mDAP: meso-diaminopimelic acid; MurNAc: N-acetylmuramic acid; iE-DAP: γ-D-
glutamyl-meso-diaminopimelic acid; M-Tetra-DAP: MurNAc-L-Ala-D-Glu-mDAP-D-Ala; M-TriDAP: MurNAc-L-Ala-D-Glu-mDAP
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accumulation of misfolded proteins within the ER lumen, which, if 
left unchecked, can lead to cellular injury and apoptosis. Thus, ER 
stress, which can be induced by various cellular stressors including 
microbial infection, can be construed as a danger signal indicative 
of cellular dysfunction. As a means of restoring ER function and 
cellular homeostasis, ER stress triggers the activation of various 
signaling pathways including inflammation that constitute the un-
folded protein response (UPR).29 Chemical inducers of ER stress, 
such as thapsigargin and dithiothreitol, resulted in upregulation of 
the inflammatory cytokine IL-6, which was in part dependent on 
the presence of NOD1 and NOD2.30 In addition, infection with 
B abortus which induces ER stress also promoted an inflamma-
tory response in bone marrow-derived macrophages and in mice, 
which was reversed by the ER stress inhibitor TUCDA and was im-
paired in the absence of NOD1 and NOD2. Together, these results 
strongly suggest a PGN-independent pathway involving ER stress 
can activate NOD1 and NOD2 although the precise upstream sig-
nal sensed by NOD1 and NOD2 remains unclear. However, it has 
also been posited based on results from another study that ER 
stress per se does not activate NOD1 and NOD2; rather, cellu-
lar perturbations related to Ca2+ flux may be the main activating 
stimulus as thapsigargin, which induces ER stress by inhibiting ER 
calcium ATPase and Ca2+ accumulation in the ER lumen, resulted 
in NOD1/2-dependent cytokine production in HCT116 colon ep-
ithelial cells.31 On the other hand, other ER inducers not associ-
ated with changes in intracellular Ca2+ levels, such as tunicamycin, 
did not induce an inflammatory response via NOD1 or NOD2.31 
Furthermore, inhibitors of Ca2+ flux partially recapitulated the 
effects of thapsigargin. Therefore, it was hypothesized that in-
creases in intracellular Ca2+ can lead to endocytosis and internal-
ization of extracellular PGN fragments present in either media or 
serum to activate NOD1 or NOD2 to explain results from previous 
studies although this has not been definitely proven 31
PGN fragments from non-invasive bacteria can be trans-
ported into the eukaryotic cytosol through bacterial secretion sys-
tems where they are sensed by both NOD1 and NOD2 receptors. 
However, bacterial effector proteins belonging to the type III se-
cretion system can also activate NOD1 and NOD2 independently 
of PGN stimulation that may be related to perturbations in the cy-
toskeleton. In particular, NOD1 and NOD2 can sense the activa-
tion state of Rho GTPases, which regulate the actin cytoskeleton 
and various signal transduction pathways.32 For example, bacterial 
effector proteins such as the Salmonella type III secretion system 
protein SopE can act as a guanine nucleotide exchange factor and 
efficiently activate the Rho GTPases CDC42 and Rac1, which then 
interacts with NOD1 resulting in activation of downstream signaling 
pathways, specifically NF-κB.33,34 More specifically, the presence of 
SopE introduces membrane ruffles and recruitment of NOD1 into 
a multiprotein complex containing SopE, Rac1, CDC42, Hsp90, and 
NOD1. SopE containing a mutation that is unable to activate Rac1 
or CDC42 did not result in membrane ruffling and recruitment of 
NOD1. Similarly, Salmonella SipA, another type III secretion system 
effector protein, can colocalize with NOD1 and NOD2 and activate 
NF-κB in a NOD1- and NOD2-dependent manner, but independently 
of PGN.35 Shigella flexneri effector proteins, such as OspB and IpgB2, 
can also induce membrane ruffling resulting in recruitment of the 
guanidine exchange factor, GEF-H1, which, in turn, activates the rho 
GTPase, RhoA, leading to NF-κB activation that requires NOD1.36 
NOD2 can also interact with Rho GTPases; specifically, it was 
demonstrated that NOD2 can be co-immunoprecipitated together 
with Rac1 in HT29 colon epithelial cells with localization of NOD2 
to membrane ruffles induced by active Rac1.37 The ESX-1 bacte-
rial secretion system of Mycobacterium tuberculosis can also cause 
pore formation and cell membrane damage, resulting in activation 
of NOD2.38,39 It is, therefore, possible that under these conditions, 
what activates NOD1 and NOD2 are disturbances in the actin cyto-
skeleton structure. Consistently, treatment of the HT29 colon epi-
thelial cell line with cytochalasin D resulted in NF-κB activation that 
required NOD2 in the absence of PGN.37
4  | CELLUL AR LOC ALIZ ATION OF NOD1 
AND NOD2
Although NOD1 and NOD2 are cytosolic receptors, their activation 
is associated with localization to the plasma membrane, bacteria-
containing phagosomes, and endosomes likely reflecting points of 
bacterial and ligand entry.40-43 Association with the plasma mem-
brane by NOD1 or NOD2 also typically requires an intact LRR do-
main, and mutations in the LRR domain resulted in localization largely 
to the cytosol.42 How recruitment to intracellular membranes occurs 
remains to be fully elucidated, but may involve interaction with the 
actin cytoskeleton or interactions with proteins that can associate 
with the membrane.37,42,43 For example, NOD2 colocalizes with vi-
mentin on the cell membrane44 and is also capable of binding to Erbin 
and FRMPD2,45,46 a negative and positive regulator of NOD2 signal-
ing, respectively, on the basolateral membrane of intestinal epithelial 
cells. Rho GTPases, which regulate the actin cytoskeleton, are capa-
ble of interacting with NOD1 or NOD2 for their activation.33,44-46 It 
was also demonstrated that recruitment to the plasma membrane re-
quires lipid modifications for their recruitment to the cell membrane. 
Specifically, S-palmitoylation mediated by the ZDHHC5 enzyme, 
which has been associated with the endosomal system and is consti-
tutively localized to phagosomes, was required for membrane recruit-
ment to mount an effective immune response to PGN.47
5  | MECHANISMS OF LIGAND DELIVERY
Given their intracellular location, efficient NOD1 and NOD2 acti-
vation requires ligands to be delivered into the cytosol and entry 
be achieved by multiple routes (Figure 3, Table 1). Polymeric PGN 
undergoes phagocytosis and lysosomal digestion48 and may, there-
after, be transported to the cytosol. Ligands can be internalized by 
host cells through phagocytosis of whole bacteria, endocytosis, and 
uptake of outer membrane vesicle (OMVs).49
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There are multiple potential mechanisms by which PGN frag-
ments can enter the cell to activate NOD1 and NOD2, such as bac-
terial phagocytosis as well as endocytosis dependent on clathrin 
and dynamin.50-52 Although certain bacterial secretion systems can 
activate NOD1 and NOD2 independent of PGN, delivery of PGN 
can also occur via bacterial secretion systems as is the case with 
Helicobacter pylori, whose detection by NOD1 is dependent on an 
intact type IV secretion system and delivery of PGN.53 Also, invasive 
bacteria, such as Shigella flexneri, shed ligands into the cytosol.18
Membrane transport systems can also transport PGN fragments 
across the cellular surface into the cytosol. The peptide transporters 
of the SLC15 family were shown to mediate ligand delivery.51,52 The 
delivery process occurs through either micropinocytosis in a G pro-
tein-coupled calcium-sensing receptor (CaSR)-dependent manner or 
macropinocytosis in phagocytes.54 PepT1 (SLC15A1), which is highly 
expressed in the small intestinal epithelium as well as in the colon 
during inflammation, transports specifically MDP, but not NOD1-
activating molecules.55,56 On the other hand, PepT2 (SLC15A2), 
which is also expressed in epithelial cells, such as in the lung, was ca-
pable of actively transporting the NOD1 ligand iE-DAP, but not MDP, 
to activate inflammatory responses in a NOD1-dependent man-
ner.57,58 The relative importance in the utilization of these transport-
ers may also be dependent on cell type as PepT1, although important 
for transport of MDP into intestinal epithelial cells, was not required 
for MDP entry into macrophages, and similarly, transport of NOD1 
ligands did not involve PepT2 in HEK293T cells.51,52 Although PepT2 
was not important for MDP entry into lung epithelial cells, there was 
reduced activation of NOD2 in response to NOD2 agonists, such as 
MDP in Pept2-deficient bone marrow macrophages.57,59 Transport 
of NOD1 and NOD2 ligands out of endosomes is mediated by addi-
tional transporters, including SLC15A3 and SLC15A4 (Pht1) that are 
specifically expressed in macrophages and dendritic cells.41,52,59,60 
F I G U R E  3   Mechanisms of PGN entrance into host cells to trigger NOD signaling. Host cells can internalize PGN, such as MDP through 
different mechanisms: (A) Phagocytosis of bacteria can release PGN in the cytoplasm after degradation of bacteria on the phagosome. 
Some pathogenic bacteria can evade the phagosome and replicate in the host cell, thus releasing PGN in the cytoplasm; (B) extracellular 
PGN fragments can enter the host cell through endocytosis and transported to the cytosol through SLC15A3/4, lysosomal membrane 
transporters. Alternatively, the dipeptide transporter hPepT1, expressed in the intestine, can be also carrier-free PGN fragments toward the 
host cell; (C) some bacteria can deliver PGN into the host cell cytoplasm through its secretion system; (D) uptake of outer membrane vesicles 
(OMVs) released by Gram-negative bacteria facilitates internalization of PGN
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These studies demonstrate the importance of transporters for intra-
cellular peptidoglycan delivery and activation of NOD1 and NOD2, 
but the events occurring downstream of peptide transporters re-
main to be fully elucidated.
Gram-negative bacteria can release outer membrane vesicles 
(OMVs) that are 10-300 nm in diameter and can contain PGN frag-
ments, which can be internalized to activate NOD1 and NOD2. Both 
pathogens and commensal bacteria can produce OMVs and may be 
a mechanism by which non-phagocytic cells, such as epithelial cells, 
internalize PGN to enable NOD1 or NOD2 signaling. Pathogens, 
such as Vibrio cholerae, Helicobacter pylori, Pseudomonas aeruginosa, 
Neisseria gonorrhea, and Aggregatibacter actinomycetemcomitans, 
can produce PGN-containing OMVs that activate either NOD1 or 
NOD2.61-63 Besides pathogenic bacteria, OMVs from commensal 
bacteria such as the gut microbiota are also capable of activating 
NOD1 and NOD2 in intestinal epithelial cells.64 Although it was 
shown that OMVs can enter the host cytosol via lipid rafts located 
on the cell surface62 and that NOD1 can colocalize with OMVs at 
early endosomes,40,64 the precise mechanism of OMV entry into the 
cytosol and their localization within the cell can differ depending on 
the bacterial strain and host cell type.65,66
6  | SIGNALING PATHWAYS DOWNSTRE AM 
OF NOD1 AND NOD2
NOD1 and NOD2 regulate multiple pathways involved in a vari-
ety of cellular responses, including inflammatory responses via 
activation of NF-κB, MAPK, and type I IFNs, and autophagy (see 
Figure 4). In the absence of any stimulation, both NOD1 and NOD2 
exist in an inactive “autoinhibited” state in which the LRR domain 
folds onto the NBD and CARD domain preventing oligomeriza-
tion and engagement of proteins involved in downstream signal-
ing pathways (see Figure 4).11 Consistently deletion of the LRR 
domain or mutations that enforce oligomerization in NOD1 is suf-
ficient to induce NF-κB activation.4,67 Upon sensing their cognate 
ligands, NOD1 and NOD2 self-oligomerize via their NACHT domain 
to recruit and likewise bring into close proximity molecules of the 
adapter protein receptor-interacting serine-threonine kinase 2 
(RIPK2), which contains an N- and C-terminal CARD domain, via 
homotypic CARD-CARD interactions.3,4,67-70 This subsequently 
leads to K63-linked polyubiquitination of RIP2 within its kinase 
domain, which is required for activation of NF-κB.71 Multiple E3 
ligases are involved in the polyubiquitination of RIPK2 and include 
cIAP-TRAF complexes and Pellino3.71-73 Polyubiquitination of 
RIPK2 is necessary for recruitment of transforming growth fac-
tor B-activated kinase 1 (TAK1) and TAK1-binding proteins (TAB), 
which subsequently lead to MAPK and NF-κB activation. Non-
K63 ubiquitination of NOD2 can also occur via XIAP and leads to 
the recruitment of the linear ubiquitin chain assembly complex 
(LUBAC), which produces M1-linked ubiquitin chains that, together 
with K63-linked chains, facilitate the activation of NF-κB.74 On the 
other hand, deubiquination of RIPK2 by the deubiquitinases A20, 
OTULIN, or cylindromatosis protein (CYLD) results in downregula-
tion of NOD1 and/or NOD2 signaling.71,75-79
RIPK2 is critical for activation of both MAPK and NF-κb path-
ways. RIPK2 binds to both TAK1 and the NF-κB essential modulator 
kinase (NEMO) also known as IKKγ.71 The colocalization of NEMO 
and TAK1 promotes the subsequent phosphorylation of the IκKβ 
subunit of the inhibitor of kappa B kinase (IKK) complex by TAK1, 
which results in the phosphorylation and degradation of IκBα from 
the IKK complex. The IKK complex then drives phosphorylation 
of signal-responsive serine residues of inhibitors of kappa B (IκBs), 
which are bound to NF-κB dimers in the cytosol. IκBs undergo pro-
teasomal degradation to allow the cytoplasmic release and nuclear 
translocation of NF-κB followed by transcription upregulation of 
pro-inflammatory mediators.80 NF-κB subsequently binds to kappa B 
(κB) elements, activating transcription of inflammatory and immune 
TA B L E  1   Mechanisms of bacterial entry into cells and recognition by NOD1 and NOD2
Transport system Microbe/ligand Receptor Outcome(s) Reference(s)
Uptake of PGN-containing 
OMVs
Gram-negative bacteria including 
H pylori, P aeruginosa, V cholerae, 
A actinomycetemcomitans, B 
fragilis, and Neisseria gonorrhea
NOD1/2 Autophagy; migration of NOD1/PGN-
OMVs/RIPK2 to early endosome; 
NF-κB and MAPK; IL-8 upregulation; 




MDP and Salmonella NOD2 MDP transport across endosomal 
membranes; NF-κB/MAPK activation
41
Peptide transporter hPepT1 MDP NOD2 NF-κB activation in epithelial cell and 
IL-8 release
56
Peptide transporter PepT2 iE-DAP NOD1 NF-κB/MAPK activation 57,58
Type III secretion system-
dependent invasive 
bacteria
S flexneri; S Typhimurium NOD1 NF-κB signaling; RhoA activation; SGT1-
dependent IL-8 secretion
36,113,122
Type IV bacterial secretion 
system
MDP/Brucella abortus NOD1/2 ER stress-induced inflammation 30
Type VII ESX-1 secretion 
system
MDP/M tuberculosis NOD2 Type I IFN expression in macrophages 39
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response components. Initiation of RIPK signaling and formation of 
the TAK1 kinase complex also result in phosphorylation of MKK6 
and subsequent activation of the MAPKs, including the p38, extra-
cellular signal–regulated protein kinase (ERK), and c-Jun N-terminal 
kinase (JNK) pathways.69,81-84 Phosphorylated MAPKs then translo-
cate into the nucleus and phosphorylate AP-1 transcription factors, 
such as ATF, c-fos, c-Jun, and JDP family members, and mediate cy-
tokines, chemokines, and anti-microbial peptide expression. Thus, 
the engagement of RIPK2 and TAK1 allows NOD1 and NOD2 to up-
regulate inflammatory responses via both NF-κB and MAPKs.
Formation of the NOD1/2-RIPK2 multiprotein complex after ligand 
recognition is a critical event required for the activation NF-κB/MAPK. 
Upon ligand-induced oligomerization of NOD1/2, RIPK2 is recruited 
via CARD-CARD interactions. Structural and mutagenesis studies of 
RIPK2 demonstrated that it forms long filamentous structures that are 
bound by NOD2 and that the polymerization of RIPK2 is important 
F I G U R E  4   NOD1 and NOD2 signaling pathways. Sensing of iE-DAP and/or MDP occurs via the LRR domains by NOD1 and NOD2, 
respectively. Once activated, NOD receptors recruit the kinase RIP2 which can interact with LUBAC and the kinase complex TAK1:TAB. 
This complex of proteins can activate two different pathways: (1) activation of the IKK complex (NEMO: IKKα: IKKβ) which in turn activates 
NF-κB nuclear translocation; (2) activation of MAP kinases (eg, p38, ERK, and JNK) will activate the transcription factor AP1. Both NF-κB 
and MAPK pathways will induce gene expression of pro-inflammatory cytokines and mediators, including anti-microbial peptides (AMP). 
Alternatively, ER stress triggers the unfolded protein response (UPR) caused by accumulation of unfolded or misfolded proteins and bacterial 
infection. ER stress activates IRE1α (inositol-requiring enzyme 1α) which recruits TRAF2, NOD receptors, and RIPK2 to the ER membrane 
and initiates inflammatory response through NF-κB signaling; however, the exact mechanism of NF-κB signaling activation by ER stress is 
still unclear. A cytosolic UPR (cUPR) has been described that is required for NOD1 and NOD2 complex formation and activation of NF-κB. 
Upon PGN recognition, the heat-shock protein HSPBB8 is released from the complex with HRI and binds NOD1 or NOD2 allowing the 
folding and release of these receptors from endomembranes. This pathway is associated with NF-κB activation, although the mechanism 
is not totally known. At the bacterial entry site on the plasma membrane, NOD2 can recruit the autophagy protein ATG16L1, leading to 
elimination of intracellular pathogens. NOD1 and NOD2 signaling can also induce type I interferon expression. NOD2-RIPK2 activates 
TRAF3 which recruits TBK1 and induces the IFN-β transcription factor IRF7. In addition, NOD2 is also activated by sensing of virus-derived 
single-strand RNA (ssRNA). Binding of NOD2/TRAF3 to mitochondrial antiviral signaling (MAVS) induces activation of IRF3 which induces 
IFN-β gene expression
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for NOD2 activation.68 The assembly and stability of NOD1/2-RIPK2 
complexes require the heme-regulated inhibitor (HIR), an eIF2a kinase, 
and the associated heat-shock protein, HSPB8A, and the absence of 
these components results in impaired NF-κB-mediated production of 
inflammatory cytokines.85 As HIR promotes the solubility of NOD1 
oligomers after activation, it has been proposed that the HIR/HSPB8 
axis is necessary to promote the stability of large complexes including 
the NOD1 or NOD2 signalosome complex formation.85
NOD1 and NOD2 have also been shown to induce type I inter-
feron (IFN) signaling, which plays an important role in antiviral immu-
nity.86 For example, upon exposure to viral ssRNA, NOD2, but not 
NOD1, interacts with MAVS (mitochondrial antiviral signaling) via its 
CARD and NBD domains, resulting in activation of interferon regula-
tory factor-3 (IRF3) in a TRAF3-dependent manner and induction of 
IFNβ production.26,87 Overexpression and knockdown of NOD2 also 
affected type I IFN production in response to CMV, a dsRNA virus, 
which was also mediated, in part, by IRF3.88 The addition of MDP 
can potentiate type I IFN responses to CMV infection likely via in-
duction of TBK1/IRF3/7 pathway.89 MDP alone has also been shown 
to induce type I IFN responses,90 and this occurs via RIPK2-mediated 
activation of TBK1 and IRF5 in the context of Mycobacterium tuber-
culosis infection of macrophages.39
In the case of NOD1, although not responsive to ssRNA like 
NOD2, NOD1 has been shown to interact with dsRNA and can aug-
ment IFN-β gene expression in certain cell types mediated by RIG-I or 
MDA5/MAVS.27,28 NOD1 can also participate in type I IFN signaling 
independently of MAVS. Stimulation of intestinal epithelial cells or 
hepatocytes with NOD1 ligand (ie, iE-DAP or TriDAP) induces IFN-β 
production that is dependent on RIPK2.91,92 In particular, stimulation 
of cells with NOD1 ligand results in RIP2 binding to TRAF3, which 
then leads to recruitment and activation of TANK-binding kinase 1 
(TBK1), IκB kinase e (IKKε), and IRF7 to induce IFN-β production and 
signaling via the ISGF3 pathway.92
Activation of NOD1 and NOD2 can also lead to initiation of au-
tophagy pathways. Specifically, stimulation of various cell types with 
NOD1 or NOD2 agonists induced autophagy.93-95 This phenomenon 
also occurred in vivo in peritoneal macrophages when mice were in-
jected intraperitoneally with either NOD1 or NOD2 agonists. Induction 
of autophagy occurred independently of RIPK2 and NEMO, a compo-
nent of NF-κB signaling; rather, NOD1 and NOD2 interacted with the 
autophagy regulator ATG16L1 at the plasma membrane, triggering au-
tophagy, which can promote the sequestration of intracellular bacteria 
into autophagosomes to promote their subsequent clearance.93
7  | NOD1 AND NOD2 IN ADAPTIVE 
IMMUNIT Y
Both NOD1 and NOD2 can participate in adaptive immunity. NOD1 
and NOD2 agonists can act as adjuvants to enhance antibody pro-
duction96 and T cell responses. Immunization of NOD1-deficient 
mice with complete Freud's adjuvant, which contain both TLR4 
and NOD1 agonists, resulted in impaired antigen-specific antibody 
production and reduced numbers of IL-17, IL-4, and IFN-γ-producing 
T cells.97 This may, in part, be due to the ability of NOD1 ligand to 
induce/stimulate DC responses alone and cooperatively with TLR4 
agonists.97,98 In addition, immunization of mice with NOD1 ligand 
and ovalbumin (OVA) results in an enhanced Th2-polarized antigen-
specific response that required NOD1 function in non-hematopoi-
etic cells, possibly as a result of the NOD1-mediated induction of 
chemokines, including the Th2-promoting factor, MCP.97 Similar to 
what occurs with NOD1 ligand, systemic release of MCP occurs 
after administration of MDP to mice, and immunization of mice with 
MDP and OVA results in a Th2-polarized antigen-specific T and B cell 
response that requires NOD2 function in non-hematopoietic cells 
and in CD11c+ DCs.99,100 In particular, both NOD1 and NOD2 pro-
mote the production of thymic stromal lymphopoietin protein (TSLP) 
production by non-hematopoietic cells and upregulate OX40 ligand 
(OX40L) surface expression on DCs that are important for Th2 im-
munity.100,101 In addition, NOD2 is also capable of synergizing with 
TLR4 agonists to enhance the production of Th1-polarizing cytokines 
by DCs and prime Th1 cells as occurs with CFA immunization.99 
Thus, while co-stimulation with NOD1 and/or NOD2 collaborates 
to a Th2 response, co-stimulation with TLR agonists can synergize to 
induce Th1, Th2, or Th17 immune responses.97-99 NOD1 and NOD2 
may also promote specific T cell responses via other mechanisms 
that affect the priming function of DCs. For example, NOD2 stimu-
lation induces autophagy in DCs, which is required from MHC class 
II (MHC-II) antigen presentation and antigen-specific CD4+ T cell re-
sponses.102 NOD2 can also affect miRNA expression in DCs that can 
affect the production of specific Th17 cell–polarizing cytokines.103 
Injection of NOD1 or NOD2 ligands into mice also increases DC-
mediated cross-presentation by enhancing antigen presentation and 
co-stimulatory molecule expression on DCs.104 Altogether, these 
studies provide strong evidence for a role of NOD1 and NOD2 sign-
aling in regulating adaptive immune responses.
NOD1 and NOD2 are also expressed in B and T cells, although 
level of expression is dependent on cellular location. There are some 
data to suggest that NOD1 and NOD2 ligands can enhance B and T 
cells after B-cell receptor (BCR) and T-cell receptor (TCR) engage-
ment.105-107 Specifically, in human tonsillar B cells, NOD1 or NOD2 
activation alone by treatment with their respective ligands was in-
sufficient to trigger B cell activation or proliferation whereas the 
combination of NOD1 and NOD2 ligands and BCR activation via IgM 
or IgD stimulation resulted in enhanced cellular proliferation in vitro, 
which is further augmented by concomitant TLR stimulation.105 
Stimulation of purified CD3+ human tonsillar T cells with NOD1 or 
NOD2 ligands alone or after TCR activation with anti-CD3/CD28 
did not induce cellular proliferation or T-cell cytokine production. 
Nonetheless, in mixed cultures of tonsillar mononuclear cells, en-
hanced cellular proliferation of T cells was observed after anti-CD3/
CD28 stimulation together with NOD1/NOD2 agonists although 
the effect was relatively weak.106 With purified murine splenic CD3+ 
T cells, it was also demonstrated that NOD1 ligand can act as a 
co-stimulatory molecule to enhance IFN-γ production after stimula-
tion with anti-CD3 alone; however, the possibility of a contributing 
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factor by potential contaminating antigen-presenting cells was not 
ruled out.107 Regardless, as these studies were all performed in vitro, 
the physiologic significance of these findings remains to be deter-
mined in vivo.
8  | ROLE OF NOD1 AND NOD2 IN HOST 
DEFENSE
As sensors of peptidoglycan and regulators of key inflammatory 
pathways, such as NF-κB and MAPK, NOD1 and NOD2 play im-
portant roles in bacterial recognition and the activation of immune 
responses important for bacterial killing and clearance. Specifically, 
NOD1 and NOD2 promote host defense by inducing: (i) inflamma-
tory cytokines that have bacterial killing activity, (ii) chemokines that 
lead to the recruitment of neutrophils and macrophages to the sites 
of infection, (iii) anti-microbial peptide production by epithelial cells, 
(iv) type I IFNs, (v) reactive oxygen species, (vi) adaptive immune re-
sponses,53,108 and (vii) autophagy.
Largely through recognition of their respective peptidoglycan li-
gands, but also via peptidoglycan-independent mechanisms, NOD1 and/
or NOD2 are capable of sensing L monocytogenes,50,96,109 Streptococcus 
pneumoniae,110,111 Salmonella,35,47,85,108,112,113 Mycobacterium tuber-
culosis,94,114 Staphylococcus aureus,115,116 E coli,117-119 C pneumoniae,120 
Shigella flexeri, and Borrelia burgdorferi.18,36,121-123
Unlike NOD2 which is expressed primarily in myeloid cells, 
monocytes, macrophages, and dendritic cells,3 NOD1 is ubiquitously 
expressed such as in epithelial cells.4 Thus, a common mechanism of 
NOD1-mediated host defense against bacterial pathogens is the in-
duction of chemokines and anti-microbial peptides by epithelial cells 
that promote the recruitment of immune cells such as neutrophils 
and bacterial killing. In vitro stimulation of intestinal epithelial cells 
with NOD1 synthetic ligands results in the production of CXCL1, 
CCL2, and IL-8 that are important for recruitment of neutrophils.124 
Moreover, in vivo NOD1 stimulation can induce neutrophil recruit-
ment into the peritoneal cavity after i.p. administration of NOD1 li-
gand; this response was abolished in NOD1-deficient mice.124 The 
ability of epithelial cells to respond to bacterial stimulation via NOD1 
can be particularly important in the intestine where intestinal epi-
thelial cells have low TLR expression and are less responsive to TLR 
stimulation with lipopolysaccharide.117,125 In the case of Clostridium 
difficile which contains high NOD1- but low NOD2-stimulatory ac-
tivity, particularly in mesothelial cells, intraperitoneal injection re-
sulted in significant neutrophil recruitment in the peritoneum that 
was NOD1-dependent, and NOD1-deficient mice had increased 
mortality to C difficile colitis associated with impaired production of 
CXCL1, decreased neutrophil infiltration in the colon lamina propria, 
and reduced bacterial clearance after oral gavage.126 Besides the in-
testine, NOD1 signaling in the gastric epithelium is important in host 
defense against Helicobacter pylori infection, which, despite being 
a Gram-negative bacteria, does not activate TLR4 signaling in the 
gastric mucosa.53,127 Peptidoglycan-containing H pylori can activate 
both NF-κb and MAPK pathways that are NOD1-dependent.53,128 
NOD1-deficient mice had increased susceptibility to H pylori infec-
tion resulting in reduced production of the chemokine MIP-2 and 
increased bacterial loads.53 Other mechanisms besides chemokine 
production likely contribute to clearance of H pylori including pro-
duction of anti-microbial peptides such as β-defensins,129,130 in-
duction of autophagy-induced inflammatory responses,40,131 and 
synthesis of type I IFNs by epithelial cells.92 NOD1 also promotes 
adaptive immune responses to H pylori as NOD1-deficient mice ex-
hibit reduced IgG levels in response to H pylori OMVs,62 which may 
be related to a role for NOD1 in regulating release of processed IL-
33,132 a key driver of Th2 immune responses, and NOD1-dependent 
type I IFN production can lead to enhanced Th1 chemokine secre-
tion.92 Thus, NOD1 engages multiple pathways to mediate host re-
sistance to pathogens.
NOD2 has a more restrictive expression pattern than NOD1 with 
expression primarily in monocytes and macrophages. Besides the 
production of inflammatory cytokines, like NOD1, NOD2 can also 
upregulate chemokine production via NF-κB and MAPK pathways 
to recruit immune cells important for eradication of bacterial patho-
gens.69,133 For example, in vivo, NOD2 promotes the CC-chemokine 
ligand 2 (CCL2)-CCR2-dependent recruitment of Ly6Chigh mono-
cytes in the intestine and clearance of Citrobacter rodentium-in-
fected mice.134 S pneumoniae also induces CCL2 via NOD2, leading 
to the recruitment of inflammatory macrophages that play a role in 
bacterial clearance in the lung.111
An important function of NOD1 and NOD2 is to act coopera-
tively with Toll-like receptors (TLRs) to enhance immune responses 
against pathogenic infection as well as promote immune responses 
after tolerization by TLR ligands. For example, bone marrow-derived 
macrophages (BMDMs) or mice stimulated with the TLR4 ligand, li-
popolysaccharide (LPS), in combination with MDP, resulted in en-
hanced activation of NF-κB and increased production of IL-6 and 
TNF-α. In addition, BMDMs made insensitive or tolerant to TLRs by 
previous exposure to TLR ligands, such as LPS, exhibited enhanced 
response to NOD1 and NOD2 stimulation.135 The significance of this 
was demonstrated in vivo in which Nod1-/-Nod2-/- mice previously in-
fected with E coli had decreased bacterial clearance and mouse sur-
vival after subsequent infection with Listeria monocytogenes, which 
contains both NOD1 and NOD2 ligands. Similarly, although activa-
tion of NF-κB and MAPK and production of inflammatory cytokines 
in BMDMs to M tuberculosis were not dependent on NOD1, immune 
responses to M tuberculosis were partly mediated by NOD1 signal-
ing after tolerization of TLRs by LPS pretreatment.136 These results 
demonstrate the importance of NOD1 and NOD2 signaling in host 
defense especially in the setting of secondary bacterial infections 
when TLR responses are impaired as a result of tolerization.135
NOD1 and NOD2 signaling are also important for antiviral immu-
nity via different mechanisms. Nod2−/− mice have been known to have 
increased susceptibility against a variety of viral pathogens.26,87,137 
NOD2 is capable of interacting with ssRNA, and infection of NOD2-
expressing cells in vitro or mice in vivo with VSV, RSV, and influenza 
leads to upregulation of type I IFNs that are NOD2-dependent.26 
Infection of Nod2-/- mice with RSV develops worse lung pathology 
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compared to that of wildtype mice.26 Nod2-/- mice also exhibit re-
duced survival and clearance of influenza virus after infection, which 
is associated with impaired DC responses and reduced priming of 
CD8+ T cells to influenza.87 NOD2 is also capable of limiting influen-
za-induced lung pathology, by the induction of autophagy, and more 
specifically mitophagy, resulting in decreased mitochondrial damage 
and suppression of inflammasome activation that can contribute 
to immunopathology and morbidity.138 Although NOD1 mice can 
similarly respond to specific viruses in vitro, whether direct recog-
nition of viruses of NOD1 affects disease outcomes remains to be 
determined.
Host antiviral responses can also be potentiated by stimula-
tion of NOD1 and NOD2 by their respective PGN ligand. For ex-
ample, MDP treatment of mice infected with influenza resulted 
in the induction of type I IFNs as well as CCL2 resulting in in-
creased recruitment of inflammatory monocytes, reduced viral 
loads, improved lung pathology, and decreased mortality that was 
NOD2-dependent.139 Stimulation of NOD2 by MDP also inhibited 
cytomegalovirus (CMV) replication in vitro and was associated with 
the synergistic induction of type I IFNs by CMV and MDP.89 Liver 
sinusoidal endothelial cells stimulated with the NOD1 ligand diami-
nopimelic acid (DAP) resulted in maturation of liver sinusoidal endo-
thelial cells and increased T cell responses in vitro.140 Consequently, 
administration of DAP in vivo resulted in increased hepatitis B virus 
(HBV)-specific T cell responses in vivo and replication of HBV.140 
Mice pretreated with the NOD1 ligand iE-DAP also exhibited re-
duced CMV load after infection,91 and the combination of iE-DAP 
and MDP enhanced inhibition of CMV replicative activity which 
required type I IFNs.91 These results suggest that exposure to bac-
teria and stimulation of NOD1 and NOD2 can augment antiviral im-
munity. Conversely, it has also been demonstrated that type I IFNs 
can induce expression of NOD1 and NOD2 in BMDMs resulting in 
enhanced NF-κB/MAPK activation and inflammatory cytokine pro-
duction. Consistently, infection of bone marrow macrophages by 
murine norovirus (MNV) resulted in increased NOD1- and NOD2-
dependent activation of NF-κB/MAPK activation and production 
of TNF-α and IL-6. Although this phenomenon may have been de-
signed to enhance immune responses against a secondary bacte-
rial infection, in vivo infection by bacteria such as E coli after MNV 
infection resulted in increased inflammation and mortality in mice, 
which is reminiscent of the negative consequences of secondary 
bacterial infections in humans due to an overexuberant inflamma-
tory response.137
A role for NOD1 and NOD2 in fungal and parasitic infections has 
been less well-studied. Addition of Aspergillus fumigatus to immor-
talized human corneal epithelial cells results in increased expression 
of NOD1 and RIPK2.141 However, although knockdown of Nod1 re-
sults in reduced production of inflammatory cytokines in response 
to Aspergillus,141 in vivo infection in NOD1-deficient mice was asso-
ciated with increased survival, reduced inflammation, and improved 
clearance, suggesting that NOD1 signaling, in fact, suppresses im-
mune responses against Aspergillus, possibly due to NOD1-mediated 
reduction in Dectin-1, a C-type lectin pattern recognition receptor, 
which is important for Aspergillus killing.142 Similarly, NOD2-deficient 
mice were also protected against invasive Aspergillus and negatively 
regulated Dectin-1 expression 143. NOD2 also has negative regula-
tory role in the immune response against chitin, a polysaccharide of 
the fungal cell wall.144 Fungal chitin, which forms a component of 
PGN, induces the release of the anti-inflammatory cytokine IL-10 by 
BMDMs via NOD2 and TLR9 whereas the production of TNF-α was 
dependent on TLR2 and Dectin-1.144 Intracellular delivery of chitin 
was required and mediated by the mannose receptor, a C-type lec-
tin PRR, which is capable of actin remodeling and mediating both 
phagocytosis and endocytosis.145 Importantly, the chitin-induced 
anti-inflammatory response may play a critical role during the late 
phase of infection to allow resolution of inflammation.144
Both NOD1 and NOD2 have also been shown to sense cer-
tain parasitic infections. In particular, NOD1-deficient mice were 
more susceptible to Trypanosoma cruzi infection compared to that 
of wildtype (WT) mice. NOD2 was also shown to be important for 
resistance against Toxoplasma gondii infection by inducing Th1 re-
sponses.146 NOD2 deficiency also resulted in increased suscepti-
bility to T gondii-induced ileitis and cerebral inflammation after oral 
infection.147 The impairment in mounting Th1 responses in NOD2-
deficient mice against T gondii was not due to a defect in DC priming, 
but T cell–intrinsic role for NOD2 in regulating IL-2-deficient mice 
via non-canonical NF-κB signaling.146 However, a separate study 
was unable to demonstrate a protective role for NOD2 against T 
gondii infection or a T-cell–intrinsic function,148 which was posited 
to be due to either insufficient backcrossing of NOD2-deficient mice 
used in the previous study or differences in the gut microbiota in 
mice in different mouse facilities. NOD2 was also suggested to rec-
ognize the malarial pigment hemozoin,149 and Nod1-/-Nod2-/- mice 
exhibited reduced inflammatory cytokine production in response to 
Plasmodium berghei; however, there were no differences in survival 
or susceptibility to cerebral malaria.150 Thus, how NOD1 and NOD2 
sense parasites and whether they play a role in disease susceptibility 
remain to be fully elucidated.
9  | NOD1 AND NOD2 IN INTESTINAL 
HOMEOSTA SIS
Through their regulation of pro-inflammatory cytokines/
chemokines, anti-microbial peptides, adaptive immunity, and au-
tophagy, NOD1 and NOD2 can promote intestinal homeostasis 
by enhancing epithelial barrier function 151,152 and resistance to 
pathogen invasion that can lead to infectious colitis. Activation of 
NOD1 and NOD2 by Salmonella infection in the intestine increases 
clearance and limits the severity of Salmonella colitis in mice.108 
NOD2-mediated regulation of CCL2 secretion and Th17 responses 
protects mice against Citrobacter rodentium-induced colitis.108,134 
NOD1 signaling promotes neutrophil recruitment via the induc-
tion of chemokines which is important for reducing the sever-
ity of Clostridium difficile colitis.126 Intestinal bacterial infections 
by L monocytogenes, S flexeri, and Helicobacter hepaticus are also 
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ameliorated as a result of NOD1 and NOD2 activation via the pro-
duction of pro-inflammatory mediators, anti-microbial peptides, 
and/or bacterial autophagy.93,96,153
NOD1 and NOD2 also play other important functions to help 
maintain intestinal homeostasis. NOD2 is constitutively expressed 
in LGR5+ intestinal stem cells (ISCs) for example. Activation of 
NOD2 is associated with increased intestinal organoid-forming effi-
ciency, and in vivo treatment of mice with MDP improved intestinal 
epithelial regeneration and healing after doxorubicin-induced injury 
associated with greater stem cell activity 154 although the precise 
mechanism for this protection remains to be determined. NOD1 
signaling in non-hematopoietic cells regulates the development of 
isolated lymphoid follicles (ILFs) in the intestine, and treatment of 
germfree mice with a NOD1, but not NOD2 agonist, resulted in in-
creased ILF formation, particularly in the ileum via NOD1-dependent 
induction of CCL20 and beta-defensin 3, both of which promote the 
formation of ILFs.155 How NOD1-mediated induction of ILFs affects 
susceptibility to intestinal disease is not clear; however, the ileal bio-
film of NOD1-deficient mice contained a greater bacterial load than 
that of WT mice as well as an expansion of Gram-negative bacteria, 
including Bacteroides and Enterobacteriaceae. As ILFs are important 
sites of IgA induction,156 it is possible that an effect on IgA produc-
tion may have contributed to the altered microbiome composition 
as IgA-deficient mice exhibit similar changes.155,157 Whether these 
effects on the gut microbiota lead to disease susceptibility remains 
to be determined.
Significant evidence pointing to the importance of NOD2 in 
maintaining intestinal homeostasis comes from studies pointing 
to a link between NOD2 dysfunction and inflammatory bowel 
disease (IBD). IBD is a chronic, relapsing-remitting inflammatory 
disorder involving the gastrointestinal tract. There are two forms 
of IBD, ulcerative colitis and Crohn's disease, and they are dis-
tinguished from each other based on clinical characteristics and 
histopathologic characteristics. Ulcerative colitis affects just the 
colon, particularly the rectum, and only the surface mucosal layer. 
In contrast, Crohn's disease can affect any part of the GI tract, al-
though it occurs commonly in the ileum, and inflammation is trans-
mural and not necessarily contiguous (“skip” lesions). Although the 
pathogenesis of IBD is still not fully understood, the prevailing 
model is that combined genetic and environment factors lead 
to disruption of the integrity of the epithelial barrier, pathologic 
changes in the composition of the gut microbiome, referred to 
as dysbiosis, and aberrant immune responses to the gut microbi-
ota.158 NOD2 has been identified as a major susceptibility gene 
for Crohn's disease, and multiple polymorphisms, including loss-
of-function mutations, have been associated with increased risk of 
developing Crohn's disease159,160 (Figure 5A, Table 2). Individuals 
harboring NOD2 homozygous or compound heterozygous for 
NOD2 variants exhibit 20- to 40-fold increased risk of developing 
CD.161 Although conferring CD risk, the majority of individuals car-
rying NOD2-associated polymorphisms do not develop disease.
How NOD2 regulates susceptibility to developing IBD has 
been the focus of significant investigation, but several mechanisms 
have been proposed (Figure 5B). The most common CD-associated 
Nod2 variant is an L1007fs frameshift insertion at nucleotide 
3020 (3020insC) in the LRR domain that generates a truncated 
protein.3,159,162 Monocytes from homozygous individuals showed 
impaired cytokine response after MDP stimulation,163 which was 
similarly observed in mice BMDMs carrying the Nod2 mutation ho-
mologous to the human L1007fsinsC (Nod22939iCstop)164 or in cells 
transfected with mutant NOD2 in response to MDP.121,162 This 
mutant version of NOD2 does not localize to the plasma mem-
brane43,165 and consequently does not recruit ATG16L, thereby 
preventing the formation of autophagosomes and impairing bac-
terial clearance.93 The important of the NOD2-ATG16L pathway is 
further supported by the observation that individuals homozygous 
for the single nucleotide polymorphism rs2241880 in the ATG16L 
gene are associated with increased risk for Crohn's disease,166,167 
and cells from these individuals have defective autophagy after 
MDP stimulation.93 Crohn's disease variants in NOD2 have also 
been shown to have defective S-palmitoylation, which is required 
for plasma membrane association and optimal bacterial sensing.47 
DCs isolated from individual harboring either the 1007fsinsC Nod2 
or the Crohn's variant ATG16L T300A exhibited defective autoph-
agy, MHC-II processing, and antigen-specific CD4+ T cell responses 
against bacteria, which can reduce mucosal immunity.102 In addition, 
DCs harboring Crohn's disease Nod2 variants have impaired levels of 
mir-29 as a result of impaired NOD2 signaling, resulting in enhanced 
release of IL-23 and IL12p40 which can contribute to disease.103 It 
has also been shown that BMDMs from a different mouse strain that 
harbors the same homologous 1007fsinsC (Nod22939ic) allele exhib-
ited increased NF-κB activation and heightened cytokine responses 
consistent with the observation that Crohn's disease patients have 
increased production of inflammatory cytokines.168 Nod22939ic mice 
also exhibited increased susceptibility to chemically induced coli-
tis with dextran sulfate sodium (DSS),168 a commonly used mouse 
model that has features that recapitulate that of human IBD. The 
difference in BMDM responses to MDP between the two different 
mouse strains is not clear, but it was postulated that this discrepancy 
may be due to the addition of amino acids after the frameshift mu-
tation in Nod22939ic mice that are not present in the wildtype NOD2 
protein or in the truncated Crohn's disease-related mutant protein 
that is present in Nod22939ic mice.164
Mutations in NOD2 have been linked to disease localization to 
the ileum.169,170 Notably, Paneth cells are located in the crypts of the 
small intestine, and abnormalities in Paneth cells have been noted in 
Crohn's disease patients.171 Paneth cells are important for the pro-
duction of anti-microbial peptides (AMPs). Decreased alpha-defen-
sin levels have been observed in Crohn's disease patients with Nod2 
mutations.172 In mice, NOD2 deficiency is associated with decrease 
in AMP production, specifically cryptdins, resulting in impaired gut 
barrier function and increased susceptibility to bacterial infection.96 
Under steady-state conditions, AMPs, such as lysozyme, are synthe-
sized in the ER and transported to the Golgi, where they are packed 
into immature secretory dense core vesicles (DCV) in Paneth cells. 
NOD2 stimulation allows the proper lysozyme sorting during DCV 
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maturation, and in the absence of NOD2, lysozyme degradation and 
depletion are observed, which can contribute to decrease bacterial 
clearance.173,174 Other abnormalities in the small intestinal epithe-
lium have been observed with NOD2 deficiency, including decreased 
MUC2 expression and reduced goblet cell numbers, which may lead 
to reduced mucus production and barrier function.175
Mice that lack NOD2 or harbor the 1007fsinsC mutation do not 
develop spontaneous colitis,96,168 consistent with the fact that most 
individuals who have this mutation do not develop disease, suggest-
ing that other factors, including environmental, likely contribute to 
disease pathogenesis. There is growing evidence that pathologic 
changes in the gut microbiome, or dysbiosis, can directly contribute 
to IBD. In particular, the microbiome of IBD patients typically exhibits 
a loss of microbial diversity, expansion of Enterobacteriaceae, and loss 
of Faecalibacterium prausnitzii.176 NOD2 deficiency in mice has been 
associated with changes in microbiome composition, which may be 
related to defects in mucosal barrier function and microbial sensing. 
NOD2 knockout mice exhibited increased bacterial loads in the ileum 
as well as higher abundance of Bacteroidetes and decreased levels 
of Firmicutes in the intestine, similar to what has been observed in 
Crohn's disease patients harboring SNP13 variants, suggesting a role 
for NOD2 in regulating gut microbiome composition, which in turn 
can affect susceptibility to colitis.177-179 Consistently, fecal transplan-
tation of stool from NOD2-deficient mice into germfree mice resulted 
in increased susceptibility to DSS-induced colitis compared to that of 
germfree mice harboring microbiota from WT mice.180 In a separate 
study, NOD2-deficient mice were found to exhibit an expansion of 
Bacteroides vulgatus, which can promote piroxicam-induced small in-
testinal inflammation, resulting in further changes in the microbiota, 
including increases in Proteobacteria and decreases in Bacteroidetes 
F I G U R E  5   NOD2 Polymorphisms in IBD. (A) Mutations in the NBD are associated with Blau syndrome, and single nucleotide 
polymorphisms in the LRR domain are associated with Crohn's disease. (B) NOD2 mutations result in poor sensing of MDP fragments 
impairing NF-κB activation and decrease production of anti-microbial peptides (AMPs) by Paneth cells. NOD2 variants also fail to recruit 
ATG16L1 resulting in impaired autophagy by epithelial cells. Dysregulation of these mechanisms leads to reduced bacterial clearance and 
loss of mucosal barrier function. NOD2 is also important for maintenance of the goblet cell number and mucus secretion. In addition, loss of 
commensal bacteria homeostasis possibly related to defects in NOD2 surveillance can lead to dysbiosis, which is associated with increased 
mucosal adherence and consequent bacterial translocation. NOD2 stimulation by MDP also maintains stem cell survival through protection 
against oxidative stress-mediated cell death, and NOD2 depletion results in reduced stem cell survival and proliferation. Finally, NOD2 
variants can cause dysregulation of immune responses in the lamina propria. Defective NOD2 expressed in macrophages and DC is not able 
to suppress TLR2 signaling leading to overactivation of NF-κB and increased expression of IL-12, IL-1β, and IFN-γ, which in turn can lead to 
damage of the epithelial layer. In addition, DC autophagy-induced Treg cells are reduced favoring a dysregulated inflammation. Abbreviations: 
ATG16L1: autophagy-related protein 16-like 1; DC: dendritic cell; MDP: muramyl dipeptide; NBD: Nucleotide-binding domain; NOD2: 
nucleotide-binding oligomerization domain 2; NF-κB: nuclear factor kappa B; Th1: T-helper 1; TLR: Toll-like receptor; Treg: T regulatory cell
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and Clostridiales.175 NOD2 polymorphisms may also promote disease 
through defects in sensing protective signals from the microbiome 
that are important for gut homeostasis. For example, it has been 
shown that OMVs from the commensal Bacteroides fragilis OMVs can 
trigger the autophagy pathway in DCs, which, in turn, induces regu-
latory T cells in the gut associated with protection against chemically 
induced colitis that is NOD2-dependent.181 Thus, the loss of NOD2 
function may lead to impairment of bacterial recognition and clear-
ance resulting in aberrant inflammation through other inflammatory 
pathways, including TLRs. As NOD2 has also been shown to directly 
negatively regulate TLR signaling, defective NOD2 signaling may 
further enhance immune responses to dysbiosis and increase colitis 
susceptibility.182-184
As mentioned above, multiple mouse studies have shown a 
protective effect of NOD2 against multiple models of intestinal 
inflammation,175,180,182 and treatment of mice with MDP resulted 
in protection from both DSS- and trinitrobenzene sulfonic acid 
(TNBS)-induced colitis.185 However, there have also been studies 
demonstrating no effect of NOD2 in ameliorating DSS-induced 
colitis.186 In addition, in the SAMP1Yit/Fc (SAMP) mouse model of 
spontaneous ileitis, NOD2 deletion improved intestinal inflamma-
tion in the presence and absence of DSS and was associated with 
reduced Th2 responses.187 No significant differences in overall 
microbiome composition were observed at least on a community 
level between SAMP1Yit/Fc and wildtype mice.187 As the gut mi-
crobiome can drive host immune responses in the gut, the discrep-
ancy in findings from in vivo mouse studies is likely dependent 
not only on the strain of mice, but also on microbiome differences 
between mouse facilities. It is also important to note that it is 
unclear whether previous studies used littermate WT and Nod2-/-
 mice, and therefore, it is also possible that any observed effects in 
colitis susceptibility were related to differences in the gut micro-
biota from vertical transmission not related to NOD2 deficiency. 
Future studies using littermate mice or conventionalized GF WT 
and NOD2-deficient mice will be necessary to further delineate 
the effects of NOD2 on microbiome and colitis susceptibility.
NOD1 has also been associated with IBD although to a much 
lesser extent with gene polymorphisms associated with IBD risk 
identified in only specific populations.188-191 Although there is strong 
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pathogens, such as C difficile, there are limited studies evaluating 
the role of NOD1 in colitis. In a mouse model of colitis-associated 
tumorigenesis which combines the injection of the experimental car-
cinogen, azoxymethane (AOM), with multiple rounds of DSS to in-
duce chronic, relapsing colitis, NOD1-deficient mice were found to 
have increased severity off AOM/DSS-induced colonic inflammation 
compared to WT mice, which was associated with reduced epithelial 
barrier integrity and increased intestinal epithelial permeability.192 
Other studies evaluating Nod1-/-Nod2-/- mice also demonstrated in-
creased chemically induced colitis severity in these mice compared 
to that of wildtype mice.193 Additional studies using littermate or 
germfree Nod1-/- mice to evaluate NOD1-specific effects on colitis 
susceptibility and any microbiome-dependent contributions will need 
to be performed to further understand NOD1 function in intestinal 
homeostasis.
10  | NOD1 AND NOD2 IN SYSTEMIC 
INFL AMMATORY DISE A SE
10.1 | Type 1 diabetes
Predisposing genetic background and environmental insults can give 
rise to autoimmune disorders, such as type 1 diabetes (T1D).194-196 T1D 
is characterized by chronic inflammation involving the pancreatic islets 
of Langerhans and irreversible elimination of pancreatic beta-cells me-
diated by autoreactive T cells leading to insulin deficiency and hyper-
glycemia. Besides the well-known involvement of adaptive immunity 
in the pathogenesis T1D, there are studies to suggest a potential role 
for innate immunity, including NOD1 and NOD2, although this has 
been less well-studied. Environmental factors that affect gut perme-
ability and alterations in the composition of the intestinal microbiota 
all can affect NOD1 and NOD2 signaling to trigger inflammation and 
promote T1D.196-198 For example, in a mouse model of streptozocin-
induced T1D mice exhibited changes in the gut microbiota and trans-
location of bacteria into pancreatic lymph nodes, which preceded the 
development of T1D199 and led to upregulation of NOD2-dependent 
inflammatory responses in macrophages and DCs. Treatment of mice 
with MDP in this model promoted the development of hyperglyce-
mia.200 On the other hand, NOD2-deficient non-obese diabetic (NOD) 
mice had increased susceptibility to developing T1D although this was 
microbiota-dependent. Clearly, additional studies are necessary to 
clarify the importance of NOD1 and NOD2 in T1D.
10.2 | Type 2 diabetes
There is a compelling evidence that dysregulated NOD1 and NOD2 
signaling can also affect risk for developing type 2 diabetes (T2D), a 
chronic inflammatory condition that is typically associated with in-
sulin resistance and obesity, although studies are conflicting in terms 
of their protective versus detrimental roles.201-204 Endotoxemia due 
to changes in intestinal permeability and translocation of PAMPs 
to the circulation is observed in mouse models of T2D, which can 
give rise to inflammation and insulin resistance.205 Individuals with 
metabolic syndrome, who are at high risk for developing insulin re-
sistance and T2D, exhibit high expression and activity of NOD1.206 
Increased intestinal permeability and translocation of bacteria sys-
temically in mice on a high-fat diet (HFD) led to increased circulating 
levels of NOD1 agonists, and deficiency in NOD1 resulted in a pro-
tective effect with reduced insulin resistance, glucose intolerance, 
and HFD-induced inflammation.204,207 Administration of NOD1-
activating muropeptides also worsened glucose tolerance.207 ER 
stress is also highly associated with insulin resistance since mice 
deficient for XBP-1, a regulator of the unfolded protein response, 
develop diet-induced insulin resistance.208 Saturated fatty acids, 
which can be sensed by NOD1, also can activate the unfolded pro-
tein response and induce ER stress, via ER calcium depletion, to in-
duce inflammation and insulin resistance.209 Therefore, it is possible 
NOD1 is linked to ER stress that occurs during the development of 
HFD-induced obesity that potentiates systemic inflammation and 
predisposes to T2D.210
On the other hand, NOD2-deficient mice developed increased 
insulin resistance and adipose tissue compared to WT mice on 
HFD.203 In a separate study, Nod2-/- mice on HFD exhibited in-
creased intestinal bacterial translocation into metabolic tissues 
(eg, hepatic and adipose), which was associated with inflammation 
and insulin resistance due to the microbiota changes in NOD2-
deficient mice.211 Accordingly, mice injected with the NOD2 li-
gand MDP showed decreased insulin resistance in obese mice.202 
Altogether, these results suggest divergent roles of NOD1 and 
NOD2 in T2D development; however, the mechanisms involved 
still remain unclear.
10.3 | Atherosclerosis
Atherosclerosis is a vascular disease characterized by atheroma-
tous plaques in the intima as well as systemic inflammation. The 
cell death of vascular smooth muscle cells (VSMCs) in the ne-
crotic core of advanced plaques may imperil the atherosclerotic 
lesion and thin the protective fibrous cap due to decreased col-
lagen production, leading to cellular debris accumulation and in-
timal inflammation, causing plaque vulnerability which can lead 
to myocardial infarction.212,213 ER stress has been observed in 
VSMCs in the atherosclerotic plaques after perturbation.214,215 
NOD2 is expressed in VSMCs216 and plays protective effects in 
a vascular injury model of neointima hyperplasia by promoting 
VSMC proliferation, migration, and neointimal formation after 
vascular injury.217 NOD2-deficient VSMCs also enhance ER 
stress-induced cell death.218 Finally, NOD2 ablation promoted 
disruption of atherosclerotic lesions in ApoE-/- mice under an 
atherogenic diet.218 These data demonstrated a possible pro-
tective role of NOD2 during ER stress-induced VSMC death in 
processes related to plaque necrosis and progression of athero-
sclerotic lesions.
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11  | NOD1 AND NOD2 IN 
AUTOINFL AMMATORY DISE A SES
11.1 | Blau syndrome/early-onset sarcoidosis
The autoinflammatory granulomatous diseases Blau syndrome 
(BS) and early-onset sarcoidosis (EOS) are associated with ex-
cessive inflammation and granuloma formation. Both diseases 
are phenotypically similar, characterized by arthritis, skin rash, 
and uveitis, and histologically by the occurrence of non-caseat-
ing epithelioid granulomas that typically present between 3 and 
4 years of age.219,220 BS and EOS share a common genetic etiology, 
namely gain-of-function single nucleotide polymorphisms (SNPs) 
in the NOD2 gene leading to an autoactivation of NOD2-mediated 
NF-κB signaling.221-224 NOD2-related BS/EOS polymorphisms 
were shown to cluster into the ATP/Mg2+-binding site and helical 
domain 1 (HD1) in the NOD2 NOD domain, which may dysregulate 
ATP hydrolysis and NOD2 autoinhibition, respectively225 (Table 2). 
Complementary mutations in NOD1, however, do not mirror the 
NOD2 phenotype, which suggest that NOD1 and NOD2 are ac-
tivated and regulated by distinct methods.222 The mechanism by 
which NOD2 mutations participate in granulomatous inflamma-
tion still remains to be clarified.
While most of NOD2 mutations associated with CD suscep-
tibility are located between the NBD and LRR domains (Figure 5), 
BS mutations primarily affect the NBD domain with the missense 
mutation at position 334 (either p.R334Q or p.R334W) found to be 
the most common and severe.223,226-230 These mutations enhance 
the self-oligomerization of NOD2 increasing its activity, even in the 
absence of MDP. Consistently, it was reported that IL-1β, IL-6, and 
TNF-α levels in the plasma of BS patients were significantly higher 
than those of healthy controls.227 Overexpression of disease-caus-
ing mutations in cell lines was also associated with enhanced NF-κB 
activation.225,231
SNPs in the NOD2 associated with loss of function have also 
been described222,232 (Table 1). However, there is only weak ev-
idence pointing to NOD2 loss of function in BS development. 
Notably, in vitro NF-κB activity related to the overexpression of BS 
NOD2 mutations was not considered a good predictor of BS/EOS 
severity although the number of patients evaluated was small.233 
Also, mice carrying the BS/EOS p.Arg314Gln mutation do not de-
velop spontaneous disease, but instead show reduced circulating 
inflammatory cytokines after MDP stimulation, accompanied by 
decreased macrophage activity and RIPK2, MAPK, and NF-κB ac-
tivation in these cells.234 Thus, BS/EOS results primarily from the 
overactivation of NOD2, rather than a loss of function of NOD2 as 
observed in Crohn's disease.
11.2 | Sarcoidosis
In contrast to BS/EOS, the primary site of sarcoidosis granuloma 
formation is in the lung. Although BS and EOS were reported to 
share identical NOD2 mutations, no association has been reported 
between NOD2 and sarcoidosis.235 Instead, NOD1 polymorphisms 
were found in patients with sarcoidosis236 (Table 2). The Nod1 
796-allele was shown to diminish NF-κB activation in response to 
intracellular Cutibacterium acnes, a bacterium that has been iso-
lated from sarcoid lesions and has a slightly higher odds of being 
detected in sarcoidosis patients than in healthy individuals.236-238 
Regardless, sarcoidosis is considered a non-infectious granuloma-
tous disease, and its etiology remains unknown. NOD1 activation 
can also contribute to heightened inflammation in sarcoidosis. 
Sustained activation of p38 MAPK in response to NOD1 agonist 
and a lack of negative feedback loop via mitogen-activated pro-
tein kinase (MKP1) have also been shown to lead to inflammation 
in chronic sarcoidosis. Consistently, overexpression of MKP1 or 
chemical inhibition of p38 activation abrogated NOD1-mediated 
Th1 cytokine production.239 Additional studies evaluating bacte-
rial contributions and the function of NOD1 in the pathogenesis of 
sarcoid are still needed.
11.3 | Asthma
NOD1/NOD2/RIPK2 signaling has also been implicated in the 
development of Th2 immune responses and might play a critical 
role in the pathology of Th2-mediated conditions such as asthma 
and atopy. NOD2 is significantly upregulated in asthma patient 
tissues, and its overexpression in human airway smooth muscle 
cells (HASMC) promoted proliferation and pro-inflammatory cy-
tokine release in a manner dependent of TSLP.240 Mice immunized 
with OVA and NOD1 or NOD2 agonist exhibit Th2-skewed T cell 
responses.99,100 In a mouse model of house dust mite (HDM)-
induced asthma, ablation of RIPK2 was sufficient to diminish Th2 
inflammatory responses and pathology in the lung, indicating that 
NOD1 and NOD2 signaling can contribute to allergic airway in-
flammation.241 It was also demonstrated that NOD1-mediated 
exacerbation of allergic asthma requires the DC-derived pro-Th2 
chemokine CCL17.242 These data suggest that NOD1 and NOD2 
activation may influence the development of asthma. Importantly, 
polymorphisms in Nod1, Nod2, and Ripk2 genes were associated 
with allergy and asthma,243-246 and a genome-wide association 
study points to a link between NOD1 polymorphisms, asthma, and 
high levels of serum IgE247 (Table 2). How these polymorphisms 
affect NOD1 function and disease pathogenesis remains to be 
elucidated.
12  | CNS INFL AMMATORY DISE A SE
Both NOD1 and NOD2 have been shown to play a role in the devel-
opment of autoinflammatory disease involving the CNS, specifically 
multiple sclerosis, an inflammatory demyelinating disease, via rec-
ognition of PGN.248 PGN is present within antigen-presenting cells 
(APCs) in the CNS of multiple sclerosis (MS) patients249 as well as 
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in CNS lesions in animal models of MS,250,251 suggesting that the 
presence of PGN, possibly as a result of prior bacterial infection, 
may contribute to the pathogenesis of multiple sclerosis.252 In ex-
perimental autoimmune encephalomyelitis (EAE), a mouse model of 
multiple sclerosis, PGN can induce disease by stimulating dendritic 
cells to promote autoimmunity250 and also able to induce EAE in 
mice.250,253 Importantly, recognition of PGN via NOD1 and NOD2 
promoted EAE progression, and NOD1-/-, NOD2-/-, and RIPK2-/- mice 
were resistant to EAE progression reduced numbers of T cells and 
activated DCs in the CNS of knockout mice.248 APCs isolated from 
RIPK2-/- mice with EAE were defective in their ability to drive Th17 
effector cell differentiation, whereas RIPK2 function in T cells was 
not required for disease progression. Altogether, these findings sug-
gest that activation of NOD1 and NOD2 signaling by PGN is required 
for the activation of CNS-infiltrating DCs, resulting in reactivation of 
myelin-specific T cells, which, in turn, mediate pathogenesis of EAE. 
The clinical implication of these findings is significant as they point 
to a potential therapeutic target in the treatment of multiple sclero-
sis; however, it remains to determine the significance of NOD1 and 
NOD2 signaling in the pathogenesis of multiple sclerosis as there 
have been no polymorphisms in NOD1 or NOD2 identified that are 
associated with human disease.254
13  | CONCLUSION
It has become clear that NOD1 and NOD2, as sensors of pepti-
doglycan and cellular stress and activators of multiple signaling 
pathways involved in immunity and tissue repair, are key players 
in the maintenance of health and resistance to infectious and in-
flammatory diseases. Despite significant advances that have been 
made using mice models and in vitro systems, questions still re-
main regarding the precise mechanism by which NOD1 and NOD2 
signaling contribute to disease pathogenesis. In particular, care-
fully controlled studies that dissect and separate potential interac-
tions between NOD1/NOD2 and the gut microbiota and how this 
crosstalk affects the development, maintenance, regulation, and 
activation of the innate and adaptive immune system in health and 
in disease are still needed. Epigenetic mechanisms of NOD1 and 
NOD2 molecular signaling and the identity of NOD1 and NOD2 
interacting partners that are involved in recognition of upstream 
activators also remain to be fully elucidated. Such studies could 
lead to preventive and/or therapeutic options for health mainte-
nance or diseases related to dysfunction of NOD1/NOD2 signal-
ing pathways.
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